Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bria-OTS+
- Development stage
- Unknown
- Lead developer
- BriaCell Therapeutics
- Modality
- Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Bria-OTS+ is a next-generation, off-the-shelf (OTS) personalized cell-based immunotherapy developed by BriaCell Therapeutics. It is an enhanced version of the Bria-IMT platform, utilizing the SV-BR-1-gm breast cancer cell line that has been genetically engineered to express Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) along with additional co-stimulatory molecules such as CD80 and CD86. The therapy is designed to be off-the-shelf by using a library of cell lines that are matched to a patient's specific Human Leukocyte Antigen (HLA) type. This matching allows the engineered cells to effectively present tumor-associated antigens to the patient's T cells, while the expressed GM-CSF and co-stimulatory molecules provide the necessary signals to activate a robust anti-tumor immune response. Bria-OTS+ is currently being investigated for the treatment of advanced solid tumors, including breast cancer and prostate cancer, aiming to provide a more potent and targeted immune activation than earlier iterations.
- Brand names
- Bria-OTS+
- Other names
- Bria-OTS Plus
02
Targets
IFN-α (Interferon alpha-7)GM-CSF (Granulocyte-macrophage colony-stimulating factor)
Beyond the preview
Go deeper on Bria-OTS+.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bria-OTS+.